Enhancement of gag-specific but reduction of env- and pol-specific CD8 + T cell responses by simian immunodeficiency virus nonstructural proteins in mice

AIDS Research and Human Retroviruses

Volumn 28, Issue 4, 2012, Pages 374-383

  Zhang, Yinfeng ^a,b   Sun, Caijun ^a,c   Feng, Liqiang ^a,c   Xiao, Lijun ^a,b   Chen, Ling ^a,c  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; POL PROTEIN; REV PROTEIN; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIF PROTEIN; VIF VPX TAT FUSION PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN; VPR PROTEIN; VPR REV NEF FUSION PROTEIN;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE CONSTRUCT; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RECOMBINANT PLASMID; SIMIAN IMMUNODEFICIENCY VIRUS; STRUCTURAL GENE;

ANIMALS; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG DESIGN; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; MICE; MICE, INBRED C57BL; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84859196416     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0061     Document Type: Article

References (49)

1. Cohen J: Aids research - Promising AIDS vaccine's failure leaves field reeling. Science 2007;318:28-29.
2. Barouch DH: Challenges in the development of an HIV-1 vaccine. Nature 2008;455:613-619.
3. Moog C: Immune responses that correlate with HIV-1 protection? AIDS 2008;22:1461-1462.
4. Letvin NL, Rao SS, Dang V, et al.: No evidence for consistent virus-specific immunity in simian immunodeficiency virusexposed, uninfected rhesus monkeys. J Virol 2007;81:12368-12374.
5. Heeney JL and Plotkin SA: Immunological correlates of protection from HIV infection and disease. Nat Immunol 2006;7:1281-1284.
6. Friedrich TC, Valentine LE, Yant LJ, et al.: Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication. J Virol 2007;81:3465-3476.
7. Jin X, Bauer DE, Tuttleton SE, et al.: Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999;189:991-998.
8. Liu J, O'Brien KL, Lynch DM, et al.: Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009;457:87-91.
9. Yang OO: Retracing our STEP towards a successful CTL-based HIV-1 vaccine. Vaccine 2008;26:3138-3141.
10. Sekaly RP: The failed HIV Merck vaccine study: A step back or a launching point for future vaccine development? J Exp Med 2008;205:7-12.
11. Benlahrech A, Harris J, Meiser A, et al.: Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci USA 2009;106:19940-19945.
12. Hutnick NA, Carnathan DG, Dubey SA, et al.: Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4(+) T cells. Nat Med 2009;15:876-878.
13. O'Brien KL, Liu J, King SL, et al.: Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 2009;15:873-875.
14. Steinbrook R: One step forward, two steps back: Will there ever be an AIDS vaccine? New Engl J Med 2007;357:2653-2655.
15. Watkins DI, Burton DR, Kallas EG, et al.: Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008;14:617-621.
16. Wilson NA, Reed J, Napoe GS, et al.: Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 2006;80:5875-5885.
17. Hansen SG, Vieville C, Whizin N, et al.: Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009;15:293-299.
18. Wilson NA, Keele BF, Reed JS, et al.: Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol 2009;83: 6508-6521.
19. Gallo RC: Tat as one key to HIV-induced immune patho-genesis and Tat (correction of Pat) toxoid as an important component of a vaccine. Proc Natl Acad Sci USA 1999;96: 8324-8326.
20. Pollard VW and Malim MH: The HIV-1 Rev protein. Annu Rev Microbiol 1998;52:491-532.
21. Emerman M and Malim MH: HIV-1 regulatory/accessory genes: Keys to unraveling viral and host cell biology. Science 1998;280:1880-1884.
22. Altfeld M and Rosenberg ES: The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1. Curr Opin Immunol 2000;12:375-380.
23. Brander C and Walker BD: T lymphocyte responses in HIV-1 infection: Implications for vaccine development. Curr Opin Immunol 1999;11:451-459.
24. Li L, Li HS, Pauza CD, et al.: Roles of HIV-1 auxiliary proteins in viral pathogenesis and host-pathogen interactions. Cell Res 2005;15:923-934.
25. Betts MR, Yusim K, and Koup RA: Optimal antigens for HIV vaccines based on CD8+ T response, protein length, and sequence variability. DNA Cell Biol 2002;21:665-670.
26. Yu XG, Addo MM, Rosenberg ES, et al.: Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. J Virol 2002;76: 8690-8701.
27. Addo MM, Yu XG, Rathod A, et al.: Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003;77: 2081-2092.
28. Altfeld M, Addo MM, Eldridge RL, et al.: Vpr is preferentially targeted by CTL during HIV-1 infection. J Immunol 2001;167:2743-2752.
29. Addo MM, Altfeld M, Rathod A et al.: HIV-1 Vpu represents a minor target for cytotoxic T lymphocytes in HIV-1-infection. AIDS 2002;16:1071-1073.
30. Cao J, McNevin J, Holte S, et al.: Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol 2003;77:6867-6878.
31. Frahm N, Korber BT, Adams CM, et al.: Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 2004;78:2187-2200.
32. Cafaro A, Caputo A, Fracasso C, et al.: Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 1999;5:643-650.
33. Nilsson C, Makitalo B, Berglund P, et al.: Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara. Vaccine 2001;19:3526-3536.
34. Osterhaus AD, van Baalen CA, Gruters RA, et al.: Vaccination with Rev and Tat against AIDS. Vaccine 1999;17:2713-2714.
35. Vogel TU, Reynolds MR, Fuller DH, et al.: Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J Virol 2003;77:13348-13360.
36. Sun C, Zhang L, Zhang M, et al.: Induction of balance and breadth in the immune response is beneficial for the control of SIVmac239 replication in rhesus monkeys. J Infect 2010;60:371-381.
37. Hel Z, Tsai WP, Tryniszewska E, et al.: Improved vaccine protection from simian AIDS by the addition of nonstruc-tural simian immunodeficiency virus genes. J Immunol 2006;176:85-96.
38. Hel Z, Johnson JM, Tryniszewska E, et al.: A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine. Vaccine 2002;20:3171-3186.
39. Ryan MD, King AMQ, and Thomas GP: Cleavage of foot-and-mouth-disease virus polyprotein is mediated by residues located within a 19 amino-acid-sequence. J Gen Virol 1991;72:2727-2732.
40. Fang JM, Qian JJ, Yi SL, et al.: Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 2005;23:584-590.
41. Casimiro DR, Tang A, Chen L, et al.: Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003;77:7663-7668.
42. Gorelick RJ, Benveniste RE, Lifson JD, et al.: Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: Utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost. J Virol 2000;74:11935-11949.
43. Ranki A, Lagerstedt A, Ovod V, et al.: Expression kinetics and subcellular localization of HIV-1 regulatory proteins Nef, Tat and Rev in acutely and chronically infected lym-phoid cell lines. Arch Virol 1994;139:365-378.
44. Patterson LJ, Malkevitch N, Pinczewski J, et al.: Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. J Virol 2003;77:8607-8620.
45. Gavioli R, Cellini S, Castaldello A, et al.: The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS. Vaccine 2008;26:727-737.
46. Zhao J, Voltan R, Peng B, et al.: Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag. Virology 2005;342:1-12.
47. Carl S, Greenough TC, Krumbiegel M, et al.: Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS. J Virol 2001;75:3657-3665.
48. Conti L, Rainaldi G, Matarrese P, et al.: The HIV-1 vpr protein acts as a negative regulator of apoptosis in a human lymphoblastoid T cell line: Possible implications for the pathogenesis of AIDS. J Exp Med 1998;187:403-413.
49. Viscidi RP, Mayur K, Lederman HM, and Frankel AD: Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science 1989;246:1606-1608.